Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost
ophthalmic solution are administered once daily for 7 days and the effect on the blood
concentration of carteolol and latanoprost in OPC-1085EL ophthalmic solution by formulating
the combination drug will be determined.